Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Loncar Cancer Immunotherapy ETF (CNCR)

Loncar Cancer Immunotherapy ETF (CNCR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family Exchange Traded Concepts
  • Assets Under Management 41,671,800
  • Market Capitalization, $K 41,672
  • Shares Outstanding, K 1,550
  • 60-Month Beta 1.39
  • Price/Earnings ttm 0.00
  • Annual Dividend & Yield 0.35 (1.31%)
  • Most Recent Dividend 0.350 on 12/28/17
  • Management Fee 0.79%
  • Sectors:

    ETFs - Biotech

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.70 +7.12%
on 06/16/20
28.10 -2.03%
on 06/23/20
+1.41 (+5.40%)
since 06/15/20
3-Month
21.33 +29.07%
on 04/16/20
28.10 -2.03%
on 06/23/20
+6.27 (+29.50%)
since 04/15/20
52-Week
12.00 +129.42%
on 03/16/20
28.10 -2.03%
on 06/23/20
+6.28 (+29.56%)
since 07/15/19

Most Recent Stories

More News
Moderna Inches Closer to Coronavirus Vaccine: ETFs to Shine

Moderna plans to begin the Phase 3 study of mRNA-1273 this month.

PFE : 35.72 (+1.39%)
MRNA : 80.22 (+6.90%)
IBB : 142.62 (+1.68%)
CNCR : 27.53 (+3.11%)
XBI : 117.24 (+2.13%)
BBH : 172.76 (+1.43%)
FBT : 176.06 (+2.05%)
BTEC : 47.38 (+3.48%)
IDNA : 40.22 (+2.65%)
GERM : 31.60 (+0.90%)
How to Tap Red-Hot Moderna Stock With ETFs

Moderna shares have surged more than 280% so far this year on the positive development of coronavirus vaccine.

MRNA : 80.22 (+6.90%)
IBB : 142.62 (+1.68%)
CNCR : 27.53 (+3.11%)
XBI : 117.24 (+2.13%)
BBH : 172.76 (+1.43%)
BTEC : 47.38 (+3.48%)
IDNA : 40.22 (+2.65%)
GERM : 31.60 (+0.90%)
Moderna a Step Closer to Coronavirus Vaccine: ETFs to Gain

Moderna informs that the final-stage trial's primary aim will be to prevent the spread of coronavirus.

JNJ : 148.26 (+0.23%)
AZN : 58.00 (+7.45%)
MRNA : 80.22 (+6.90%)
IBB : 142.62 (+1.68%)
CNCR : 27.53 (+3.11%)
XBI : 117.24 (+2.13%)
BBH : 172.76 (+1.43%)
IDNA : 40.22 (+2.65%)
Stocks & ETFs Beneficiaries of Coronavirus Vaccine Ramp-Up

Efforts in formulating a coronavirus vaccine are heating up. These stocks and ETFs look to be the largest beneficiaries.

AZN : 58.00 (+7.45%)
MRNA : 80.22 (+6.90%)
GSK : 41.95 (+3.07%)
NVAX : 111.15 (+1.07%)
CNCR : 27.53 (+3.11%)
INO : 24.51 (-6.49%)
PTH : 132.26 (+1.96%)
BBC : 43.24 (+2.31%)
BTEC : 47.38 (+3.48%)
ARKG : 57.58 (+3.22%)
IDN : 7.44 (+3.33%)
VXRT : 14.49 (-14.61%)
GNOM : 18.70 (+3.00%)
Is Moderna Winning the COVID-19 Vaccine Race? ETFs to Gain

Moderna has presented positive interim data from a phase I study evaluating its mRNA-based coronavirus vaccine candidate.

JNJ : 148.26 (+0.23%)
SNY : 53.27 (+2.23%)
AZN : 58.00 (+7.45%)
MRNA : 80.22 (+6.90%)
GSK : 41.95 (+3.07%)
NVAX : 111.15 (+1.07%)
IBB : 142.62 (+1.68%)
CNCR : 27.53 (+3.11%)
XBI : 117.24 (+2.13%)
BBH : 172.76 (+1.43%)
IDNA : 40.22 (+2.65%)
Biotech ETFs to Gain From Latest Advancements in Cancer Drugs

The rising incidence of cancer cases has encouraged several major pharmaceutical and biotech players to invest substantially in the developments of drugs.

AZN : 58.00 (+7.45%)
PFE : 35.72 (+1.39%)
MRK : 79.44 (+1.52%)
LLY : 165.45 (+0.96%)
MYGN : 11.85 (+2.78%)
IMMU : 41.16 (+1.25%)
IBB : 142.62 (+1.68%)
CNCR : 27.53 (+3.11%)
XBI : 117.24 (+2.13%)
PBE : 61.24 (+2.35%)
Healthcare & Biotech ETFs Digest GILD's Failure News: 5 Winners

Biotech and healthcare ETFs were pretty stable on Apr 23 despite the news that Gilead's Remdesivir failed to improve Covid-19 patients' condition.

GILD : 76.65 (-0.70%)
IBB : 142.62 (+1.68%)
CNCR : 27.53 (+3.11%)
BBH : 172.76 (+1.43%)
FBT : 176.06 (+2.05%)
PTH : 132.26 (+1.96%)
IHF : 200.43 (+1.40%)
IHE : 160.29 (+1.90%)
XPH : 44.69 (+2.92%)
SBIO : 43.06 (+2.38%)
XHS : 71.31 (+3.63%)
PBE : 61.24 (+2.35%)
IDNA : 40.22 (+2.65%)
4 Top Sectors of Last Week & Their Winning ETFs

These sectors topped last week and beat the broader market in a sweeping move.

JNJ : 148.26 (+0.23%)
GILD : 76.65 (-0.70%)
ABT : 96.73 (+2.01%)
PTF : 100.06 (-0.07%)
AMLP : 23.79 (+5.27%)
CNCR : 27.53 (+3.11%)
BBH : 172.76 (+1.43%)
IBUY : 76.74 (+2.58%)
MLPA : 26.30 (+5.42%)
ARKK : 80.93 (+2.68%)
CLIX : 79.34 (-0.54%)
AMU : 8.09 (+5.74%)
ARKG : 57.58 (+3.22%)
ONLN : 56.55 (+0.62%)
Coronavirus Scare Supports These Biotech ETFs & Stocks

Growing coronavirus concerns provide some support to these biotech ETFs and stocks amid a massive market sell-off.

IBB : 142.62 (+1.68%)
CNCR : 27.53 (+3.11%)
BBH : 172.76 (+1.43%)
ARKG : 57.58 (+3.22%)
AYTU : 1.3200 (+1.54%)
FTSV : 95.51 (+0.05%)
VIR : 50.67 (+2.20%)
IDNA : 40.22 (+2.65%)
CODX : 17.66 (-2.48%)
CNTG : 11.93 (-4.02%)
Biotech Leading in Q4: Best ETFs & Stocks

We highlight five biotech ETFs and stocks that are leading the market in Q4.

SNY : 53.27 (+2.23%)
MRK : 79.44 (+1.52%)
RHHBY : 44.7300 (+0.56%)
NVS : 87.87 (+0.46%)
CNCR : 27.53 (+3.11%)
SBIO : 43.06 (+2.38%)
XBI : 117.24 (+2.13%)
BBC : 43.24 (+2.31%)
THOR : 67.99 (unch)
SRPT : 169.66 (+1.74%)
GBT : 73.01 (+3.81%)
VRTX : 295.11 (+0.44%)
AXSM : 82.09 (+3.36%)
CLSD : 1.8700 (+11.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade CNCR with:

Fund Summary

The Loncar Cancer Immunotherapy ETF seeks investment results that correspond generally to the price and yield per for mance, before fees and expenses, of the Loncar Cancer Immunotherapy Index.

See More

Top 10 Holdings

Name % Holdings

See More

Key Turning Points

2nd Resistance Point 27.84
1st Resistance Point 27.68
Last Price 27.53
1st Support Level 27.27
2nd Support Level 27.02

See More

52-Week High 28.10
Last Price 27.53
Fibonacci 61.8% 21.95
Fibonacci 50% 20.05
Fibonacci 38.2% 18.15
52-Week Low 12.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar